"The US Food and Drug Administration (FDA) has approved a foam containing calcipotriene and betamethasone dipropionate (Enstilar, Leo Pharma Inc) for topical treatment of plaque psoriasis in adults 18 years of age and older, according to a "...
Very few instances of contact allergic reactions to anthralin have been reported. However, transient primary irritation of uninvolved skin surrounding the treated lesions is more frequently seen and may occasionally be severe. Application of Dritho-Scalp must be restricted to the psoriatic lesions. If the initial treatment produces excessive soreness or if the lesions spread, reduce frequency of application and, in extreme cases, discontinue use and consult physician. Some temporary discoloration of hair and fingernails may arise during the period of treatment but should be minimized by careful application. Dritho-Scalp may stain skin, hair or fabrics. Staining of fabrics may be permanent, so contact should be avoided.
Read the Dritho-Scalp (anthralin) Side Effects Center for a complete guide to possible side effects
No information provided.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 5/26/2011
Additional Dritho-Scalp Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.